Literature DB >> 7074983

Enantiomers of indacrinone: a new approach to producing an isouricemic diuretic.

E H Blaine, G M Fanelli, J D Irvin, J A Tobert, R O Davies.   

Abstract

Racemic indacrinone is a potent loop diuretic with transient uricosuric properties in certain nonhuman primates and in man. After chronic treatment, hyperuricemia develops presumably because of enhanced proximal tubular urate reabsorption secondary to extracellular fluid volume contraction. The natriuretic and uricosuric activities are associated with both enantiomers, but the (-)-enantiomer is significantly more potent as a natriuretic agent than the (+). Acutely, in Cebus monkeys, both enantiomers appear to have similar uricosuric activity. The difference in the natriuretic potency between the two enantiomers provides the possibility of altering the enantiomer ratio from its naturally occurring 1:1 ratio to another combination which would enhance the uricosuric action [more (+) relative to (-)] while preserving the potent natriuretic action of the (-). In healthy volunteers, a 1:4 ratio [(-):(+)] was isouricemic after 7 days of treatment and a 1:8 mixture lowered mean serum urate by 13%. Presumably, the desired ratio of (-):(+) will be in the range 1:4-1:9. Further enhancement of the diuretic profile of this compound may be obtained by adding sufficient amiloride to produce isokalemia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7074983     DOI: 10.3109/10641968209061582

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  3 in total

1.  Comparative acute ototoxicity of loop diuretic compounds.

Authors:  L P Rybak; C Whitworth; V Scott
Journal:  Eur Arch Otorhinolaryngol       Date:  1991       Impact factor: 2.503

Review 2.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

Review 3.  Diuretics. Clinical pharmacology and therapeutic use (Part II).

Authors:  A Lant
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.